Literature DB >> 26982574

Hind limb perconditioning renoprotection by modulation of inflammatory cytokines after renal ischemia/reperfusion.

Zahra Sedaghat1,2, Mehri Kadkhodaee2, Behjat Seifi2, Eisa Salehi3.   

Abstract

Purpose Renal ischemia/reperfusion (I/R) injury is a common clinical problem associated with significant mortality and morbidity. One newly described strategy to reduce this damage is remote perconditioning (RPEC), in which short-time ischemia of a limb during renal ischemia reduces the I/R-induced kidney injury. This study aimed to assess whether RPEC confer protection through changes in pro-inflammatory mediators. Methods Rats were subjected to right nephrectomy and randomized into: sham (no intervention), I/R (subjected to 45-min left renal ischemia) and RPEC group (subjected to four cycles of 5-min I/R of the femoral artery administered during renal ischemia). After 24-h, blood, urine, and kidney samples were collected. Biochemical indicators of renal dysfunction were measured in the cases of Neutrophil gelatinase-associated lipocalin (NGAL), and N-acetyl-B-diglucosaminidase (NAG) activity. Inflammatory cytokines [interleukin (IL)-6 and tumor necrosis factor-alpha, TNF-α] expression in the renal tissues as well as Periodic acid-Schiff stained histological sections were evaluated. Results I/R resulted in renal dysfunction, as evidenced by higher renal NGAL expression and urinary NAG activities. This was accompanied by increased TNF-α and IL-6 expressions as well as histological changes in this group. However, RPEC improved renal histology and function compared with the I/R group. Furthermore, the RPEC group showed decreases in TNF-α and IL-6 expression. Conclusions These results suggest that RPEC reduces the dysfunction and injury associated with I/R of the kidney. This technique reduced the pro-inflammatory cytokine in the kidney. RPEC could be a promising strategy against I/R-induced acute kidney injury partly by down-regulation of inflammatory mediators.

Entities:  

Keywords:  Inflammation; ischemia; kidney; remote perconditioning; reperfusion injury

Mesh:

Substances:

Year:  2016        PMID: 26982574     DOI: 10.3109/0886022X.2016.1155387

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

1.  Involvement of neuronal pathways in the protective effects of hindlimb perconditioning during renal ischemia.

Authors:  Zahra Sedaghat; Mehri Kadkhodaee; Behjat Seifi; Parisa Ahghari; Khalil Pourkhalili; Zahra Akbari; Mehdi Sadeghi
Journal:  Exp Ther Med       Date:  2017-03-02       Impact factor: 2.447

2.  [Clinical effect and mechanism of hemoperfusion in treatment of children with severe abdominal Henoch-Schönlein purpura].

Authors:  Ying Zhu; Yang Dong; Da-Liang Xu; Jia-Yun Jiang; Lin Wu; Rui-Juan Ke; Shao-Han Fang; Yin Peng
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-05

3.  The role of nitric oxide in the protective action of remote ischemic per-conditioning against ischemia/reperfusion-induced acute renal failure in rat.

Authors:  Firouzeh Gholampour; Leila Khangah; Jafar Vatanparast; Hamid Reza Karbalaei-Heidari; Seyed Mohammad Owji; Aminollah Bahaoddini
Journal:  Iran J Basic Med Sci       Date:  2018-06       Impact factor: 2.699

4.  Inducible and endothelial nitric oxide synthase distribution and expression with hind limb per-conditioning of the rat kidney.

Authors:  Zahra Sedaghat; Mehri Kadkhodaee; Behjat Seifi; Eisa Salehi
Journal:  Arch Med Sci       Date:  2019-06-20       Impact factor: 3.318

5.  Changes of inflammatory mediators and oxidative stress indicators in children with Henoch-Schönlein purpura and clinical effects of hemoperfusion in the treatment of severe Henoch-Schönlein purpura with gastrointestinal involvement in children.

Authors:  Ying Zhu; Yang Dong; Lin Wu; Fang Deng
Journal:  BMC Pediatr       Date:  2019-11-04       Impact factor: 2.125

6.  Protective Role of Sulodexide on Renal Injury Induced by Limb Ischemia-Reperfusion.

Authors:  Tao Yuan; Ni Yang; Wei Bi; Jinwen Zhang; Xueyan Li; Long Shi; Yang Liu; Xiang Gao
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-30       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.